Preventing blood clots in genitourinary cancer with rivaroxaban
Treatments studied
Part of Cancer, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether rivaroxaban, a blood thinner pill, can help prevent dangerous blood clots in people with certain genitourinary cancers who are starting cancer treatment. It may lower clot risk, but it also has bleeding-risk tradeoffs that the study will monitor closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an active bladder, testis, ureter/renal pelvis, kidney, urethra, or penis cancer (but not prostate cancer), and you’re starting treatment
- You’re age 18 or older
- You plan to start systemic cancer therapy (chemo, targeted therapy, anti-cancer immunotherapy), and it’s expected to last at least 8 weeks
- You do not need blood thinners for another reason during the study (prevention or treatment dosing)
- You can take rivaroxaban safely—no known allergy, no major drug interactions that affect rivaroxaban, and kidney function is not severely reduced
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether continuing a lower dose of blood thinners can prevent another blood clot in cancer patients who have had a clot in an arm or chest catheter. It may help find a safer way to prevent future clots.
This trial is testing a program to help prevent blood clots in people with cancer who are starting a new type of cancer treatment, like chemotherapy or targeted therapy. The goal is to see if better prevention strategies can keep you safe during treatment.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
This trial tests whether a daily statin (rosuvastatin) can help prevent dangerous blood clots in people with advanced cancer who are starting new cancer therapy. It is for those at medium or high risk for clots, based on a simple risk score.
This study compares two daily pills, aspirin and rivaroxaban, to find which is better at preventing dangerous blood clots in people newly diagnosed with multiple myeloma who are at high risk. Participants will be randomly assigned to one of the two treatments.
This study compares two blood-thinning medications, edoxaban and apixaban, in people who have both cancer and a blood clot. The goal is to see which one works better and is safer for preventing another clot while treating your cancer.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.